Share This Page
Suppliers and packagers for endometrin
✉ Email this page to a colleague
endometrin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Ferring | ENDOMETRIN | progesterone | INSERT;VAGINAL | 022057 | NDA | Ferring Pharmaceuticals Inc. | 55566-6500-3 | 1 CARTON in 1 CARTON (55566-6500-3) / 21 BLISTER PACK in 1 CARTON (55566-6500-2) / 1 INSERT in 1 BLISTER PACK (55566-6500-1) | 2007-06-21 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: ENDOMETRIN
Introduction
ENDOMETRIN, a seminal pharmaceutical product used primarily for endometrial support in assisted reproductive procedures, is an integral part of infertility treatments. Comprising natural progesterone, ENDOMETRIN helps prepare the endometrial lining for implantation, enhancing pregnancy success rates. Its widespread use in fertility clinics globally underscores the importance of a robust supply chain. This article delineates the key suppliers, manufacturing landscape, and strategic considerations for stakeholders involved in the procurement and distribution of ENDOMETRIN.
Overview of ENDOMETRIN and Its Market
ENDOMETRIN’s active pharmaceutical ingredient (API) is natural progesterone, extracted either from plant sources or synthesized via biotechnological methods. The product is commonly available as vaginal inserts, gels, or suppositories, with the vaginal insert form being predominant.
The global market for fertility drugs, including ENDOMETRIN, is projected to grow at a compound annual growth rate (CAGR) exceeding 8% through 2026, driven by increasing infertility rates and advancements in reproductive technologies. Ensuring dependable supply remains critical for clinics and pharmaceutical distributors worldwide.
Manufacturers of ENDOMETRIN API and Formulations
1. Ferring Pharmaceuticals
Ferring Pharmaceuticals is the original developer and primary global supplier of ENDOMETRIN. The company manufactures both the active ingredient and the finished dosage forms. With a strong presence across Europe, North America, and select Asian markets, Ferring maintains extensive manufacturing facilities dedicated to reproductive health solutions.
- Manufacturing Facilities: Their primary API production occurs in dedicated biopharmaceutical plants in Europe.
- Supply Chain: Ferring manages a tightly controlled supply chain with quality assurance aligned with regulatory standards like EMA and FDA.
2. Merck KGaA (EMD Serono)
Merck KGaA's EMD Serono division produces comparable formulations of natural progesterone for fertility treatments, including vaginal inserts similar to ENDOMETRIN.
- Manufacturing Capacity: They have factories aligned with stringent quality standards.
- Market Reach: Strong presence in Europe and North America ensures a stable supply to leading fertility clinics.
3. Other Regional Suppliers and Contract Manufacturers
In addition to these global leaders, several regional or contract manufacturing organizations (CMOs) produce progesterone APIs or finished products for local markets:
- Daiichi Sankyo: Offers fertility medications including progesterone formulations under different brand names.
- Gattefossé: Specializes in excipients and formulation support, indirectly affecting ENDOMETRIN formulations.
- Contract Manufacturers: Numerous CMOs in India, China, and Eastern Europe produce generic or branded progesterone products, often for export.
4. Generics and Biosimilars
As patent exclusivity periods expire, generic manufacturers enter the market:
- Indian Pharmaceutical Companies: Sun Pharma, Cipla, and Lupin have developed generic progesterone products, sometimes supplying formulations similar to ENDOMETRIN.
- Brazilian and Latin American Manufacturers: Several local producers supply competitive options, primarily in emerging markets.
Supply Chain and Regulatory Considerations
Regulatory Approvals: Suppliers must comply with regulations from agencies such as the FDA (U.S.), EMA (Europe), and MHRA (UK). Regulatory approvals influence manufacturing standards, batch release procedures, and market access.
Quality Assurance: Due to the sensitive role of progesterone in fertility treatments, suppliers adhere to Good Manufacturing Practices (GMP). Certifications from international bodies bolster credibility.
Supply Risks: Disruptions can arise from geopolitical issues, raw material shortages, or manufacturing outages. The COVID-19 pandemic highlighted vulnerabilities in global supply chains for active pharmaceutical ingredients.
Strategic Sourcing and Market Dynamics
Diversification of Suppliers
Healthcare providers increasingly pursue supply chain diversification to mitigate risks associated with dependency on a singular supplier, especially for high-demand products like ENDOMETRIN.
Local Manufacturing Initiatives
Some markets promote local GMP production to reduce reliance on imported supplies, ensuring quicker delivery and compliance with regional regulations.
Emergence of Biosimilars
The entry of biosimilar products driven by patent expirations can influence pricing and availability, compelling stakeholders to evaluate cost-effectiveness against established brands like ENDOMETRIN.
Emerging Trends and Future Outlook
- Biotechnological Advancements: Innovation in bioproduction may lower costs and improve supply stability.
- Generic Competition: Increased manufacturing of generics can lead to price reductions and broaden access.
- Regulatory Harmonization: Efforts to streamline approvals across jurisdictions may facilitate broader supplier participation.
Conclusion
The supply landscape for ENDOMETRIN is dominated by established players like Ferring Pharmaceuticals and Merck KGaA, with a growing presence of regional and generic manufacturers. Ensuring a reliable, high-quality supply chain necessitates strategic supplier diversification, adherence to regulatory standards, and proactive risk management. As the fertility treatment market expands, stakeholders must continuously monitor technological, regulatory, and geopolitical developments influencing supplier dynamics.
Key Takeaways
- Primary Suppliers: Ferring Pharmaceuticals remains the leading producer of ENDOMETRIN globally, handling API production and formulation.
- Regional Variations: Local and regional manufacturers play critical roles in supplying the drug, especially in emerging markets.
- Supply Chain Risks: Manufacturers and healthcare providers must mitigate risks through diversification and quality assurance.
- Regulatory Impact: Regulatory approvals and compliance heavily influence supplier credibility and product availability.
- Market Evolution: Patent expirations and biosimilar development will shape future supply dynamics, potentially lowering costs and increasing access.
FAQs
1. Who is the primary manufacturer of ENDOMETRIN?
Ferring Pharmaceuticals is the original and primary global manufacturer of ENDOMETRIN, overseeing both API production and finished formulations.
2. Are there generic alternatives to ENDOMETRIN?
Yes, several generic manufacturers, mainly based in India and China, produce progesterone formulations similar to ENDOMETRIN, offering more cost-effective options in various markets.
3. What factors influence the global supply of ENDOMETRIN?
Regulatory compliance, raw material availability, manufacturing capacity, geopolitical stability, and quality standards impact supply continuity.
4. How does regulatory approval affect supply chain stability?
Strict adherence to GMP and approval by agencies such as the FDA and EMA ensure product quality and facilitate international market access, reducing supply disruptions due to non-compliance.
5. What is the future outlook for ENDOMETRIN suppliers?
Emerging biosimilars, increased generic manufacturing, and technological innovations are expected to enhance supply resilience, reduce costs, and expand access to fertility treatments worldwide.
Sources
[1] Ferring Pharmaceuticals official website.
[2] Market analysis reports on fertility drugs.
[3] EMA and FDA regulatory guidelines for reproductive pharmaceuticals.
[4] Industry publications on pharmaceutical manufacturing trends.
More… ↓
